Xarelto is Alleged to Cause Serious and Uncontrolled Internal Bleeding

Zoll, Kranz & Borgess, LLC, (ZKB), an experienced pharmaceutical and medical device litigation firm, is currently investigating claims of individuals who developed bleeding, clotting or other serious side effects or even death after taking the pharmaceutical drug, Xarelto® (rivaroxaban). Toledo, OH (PRWEB) July 17, 2014 Xarelto® (rivaroxaban) is an anticoagulant marketed in the U.S. by Janssen Pharmaceutical, a subsidiary of Johnson & Johnson. It is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee rep
Contributor
PR Web
PR Web
Lanham, Maryland
Law Marketing
1.800.345.5572
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Download

Related Documents in PR Web
MCLE Sales

Categories